VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. The episode features Shawn K. Singh, CEO of VistaGen, as he discusses the company’s innovative development pipeline and focus on bringing new, effective treatment options for anxiety, depression and other conditions involving the central nervous system (“CNS”) for which the company believes current treatment alternatives are inadequate, resulting in high unmet need. “Throughout the many years I’ve been in the [biopharma] space, I really haven’t been satisfied with the treatment alternatives that have been available to people all around the world who are suffering from mental illness, especially anxiety and depression,” Singh stated during the interview. “VistaGen provides, I think, an opportunity for tremendous excitement, given what we’re working on in our pipeline. We have three drug candidates focused on trying to go beyond the current standard of care for anxiety, depression and other CNS, or central nervous system, disorders.”
VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
A group of researchers has grown a lung-model in the lab that mimics the alveoli, which are fragile lung air sacs where lung damage as well as the COVID-19 infection occurs. This advancement has allowed Duke University researchers to observe the fight between lung cells and the SARS-CoV-2 cells at great molecular scale.
The SARS-CoV-2 virus harms the alveoli. This leads to acute respiratory distress and pneumonia, which is the main cause of death in coronavirus patients. Researchers have been hindered in coronavirus studies due to the absence of experimental models that imitate human lung tissues.
However, the team, led by Purushothama Rao Tata who is a cell biologist at Duke, has created a model using mini-lungs. To grow the organoids, AT2 cells are used. These are the stem cells that mend the parts of the lungs where SARS-CoV-2 strikes.
Prior research at Duke had demonstrated that single alveolar epithelial type-2 cells, when isolated in small dishes, multiply into millions of cells that amass into organoids that look like alveoli. These lung organoids will allow high output science, in which many experiments can be undertaken concurrently to identify the chemical lung cells produce to respond to an infection or to screen for new drug candidates.
Tata explained that the model system allowed researchers to study respiratory viruses, such as influenza, that target lung cells, in addition to studying SARS-CoV-2. “Stem Cell” journal featured the paper, which described the growth-process of the mini-lungs as well as some experiments with the COVID-19 infection, online on October 21.
The researchers worked together with their virology colleagues from the University of North Carolina and Duke to study the SARS-CoV-2 infection using the mini-lungs. Additionally, they used the advanced biosafety level 3 amenities at UNC-CH and Duke to safely handle and expose the lung organoids to the deadly viral infection. They then observed the chemical signals and the gene activity the lung cells produced after infection.
The paper’s co-author, Ralph Baric, said that this was a major breakthrough as they used cells that did not have purified cultures. Baric, a distinguished professor of microbiology, immunology and epidemiology at UNC, heads that lab that was used to confirm that COVID-19 targeted the ACE2 cell surface receptor, which led to an infection.
The lung organoids launched an inflammatory response that was brought about by interferons when the lungs were infected with the deadly virus. The scientists also noted that the lungs launched a cytokine storm of immune molecules to counter the virus.
Baric stated that his lab would use the lung organoids to better understand the dominant version of the SARS-CoV-2 virus, a new strain referred to as D614G. This strain is even more infectious as it is more efficient at recognizing lung cell ACE2 receptors.
On the other hand, Tata explained that his group would be collaborating with industry and academic partners to utilize the organoids for cell-based therapies and, in the future, work on growing a whole lung for transplantation.
An interesting company that you should watch in the biomed technology space is Predictive Oncology (NASDAQ: POAI). The company has multiple tools that make it possible for it to attain the goal of bringing precision and personalization to the treatment of different cancers.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Speakers at the annual general meeting of the Intergovernmental Forum on Mining, Minerals, Metals and Sustainable Development discussed the challenges that faced the mining sector during the virtual event. They also discussed opportunities that would facilitate the transition into a mining sector that was more sustainable and how to achieve the sustainable development goals.
Participants of the forum addressed coronavirus-related loss of employment in the mining community as a result of reduced worker mobility and border closures, as well as safety and health concerns and the increase in food insecurity and poverty. The discussions also covered technological innovation, resource taxation, climate action, artisanal and small-scale mining, gender equality and community resilience.
The main challenges facing the mining sector included:
i. Adoption of tools and approaches for gender-impact assessments. This would help to better understand the potential effect of mining projects in reducing the existing gender-inequality patterns as well as the projects’ effects on indigenous peoples’ territories and ethnic minorities.
ii. Reducing carbon emissions in mining.
iii. Developing policies for mine closure.
iv. Using digital technology to replace physical labor and equipping workers with relevant skills in remote equipment operation, automation and robotics.
v. Improving domestic revenue collection through tax reforms. This would include measures to reduce profit shifting and tax base erosion and advocate for greater transparency in the pricing of minerals.
vi. Maintaining the social license of mining firms to enable them to operate through trust building and accountability.
Forum participants were also introduced to the global campaign, Race to Zero, which strives to achieve net-zero carbon emissions by 2050 through generating leadership and support.
Representatives of the forum presented recommendations on how to improve legal frameworks for management and ESIA (Environmental and Social Impact Assessment). These recommendations sum up the best international practices in this field.
In addition to this, participants also discussed measures to execute the August 2020 Global Industry Standard on Tailings Management. The AGM was a three-day event , with more than 1,800 registered participants from 110 countries globally.
The Intergovernmental Forum, which boasts 76 government members, is the product of the World Summit on Sustainable Development (2002). The summit adopted the Johannesburg Declaration on Sustainable Development, which demanded that the health, economic, environmental and social impacts as well as benefits of mining metals and minerals throughout their life cycle be addressed. The declaration, which focuses on global conditions that pose serious threats to sustainable development, also highlighted worker safety and health issues and promoted accountability and transparency for sustainable mining.
Energy Fuels Inc. (NYSE: American: UUUU) (TSX: EFR) is one interesting company to watch in the mining sector. The company focuses on producing uranium and vanadium, both of which carry the “critical minerals” designation by the U.S. federal government. The company holds the distinction of being the largest uranium producer across the country.
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Energy Fuels (NYSE American: UUUU) (TSX: EFR) today announced that the company has produced a rare earth element (“REE”) carbonate concentrate (“REE Concentrate”) on a pilot scale at its 100% owned White Mesa Mill (the “Mill”), located near Blanding, Utah. According to the update, the REE Concentrate was produced using the Mill’s existing infrastructure and technologies from a sample of monazite sands from a North American source. A valuable natural uranium ore, monazite sands also contain high concentrations of REEs. The Mill recovered high concentrations of REEs in the monazite sands in addition to the contained uranium, which will be sold into the nuclear fuel industry. The REE Concentrate produced is of high purity and ready to be sent to a separation plant and downstream REE processing facility for final acceptance test work. “This past weekend, Energy Fuels achieved a major milestone in U.S. rare earth element production when we successfully produced a REE Concentrate from a sample of monazite sands at our White Mesa Mill,” Mark S. Chalmers, Energy Fuels’ president and CEO, said in the news release. “Our company literally accomplished REE production in months, because we utilized existing resources, infrastructure and technologies.”
Energy Fuels is a leading U.S.-based uranium mining company, supplying U 3 O 8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and is evaluating the potential to also recover rare earth elements at its White Mesa Mill. Its corporate offices are in Lakewood, Colorado near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) project in Wyoming, and the Alta Mesa ISR project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U 3 O 8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U 3 O 8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U 3 O 8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Sustainable Green Team Ltd. (SGTM) Subsidiary — Mulch Manufacturing — Awarded String of Contracts
Mulch Manufacturing has signed mulch supplier contract with Vero Beach, Florida
This — and other recent contracts — made possible due to SGTM’s recent completion of construction on its Florida Waste Management facility
Sustainable Green Team was created by bringing together three industry-leading companies
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has announced that its wholly owned subsidiary will be the official mulch supplier for Vero Beach, Florida (https://ibn.fm/OunIk). Mulch Manufacturing has signed a one-year contract with the Florida city, with two additional one-year extensions.
The Vero Beach contract is the most recent in a string of contracts awarded to Mulch Manufacturing, one of the largest producers of packaged mulch products in the country. Earlier this month, the company obtained mulch contracts from three Circle K convenient store divisions (https://ibn.fm/xBzrT). A week earlier the SGTM subsidiary landed a mulch and soil purchase agreement with the Kroger Co. to provide material for the 94 stories in its Louisville, Kentucky division (https://ibn.fm/s6yJf). And that contract came on the heels of the company being awarded a 2021 mulch packaging contract renewal from Menards Inc. (https://ibn.fm/Ek8QH).
“We are pleased to be awarded this new government contract opportunity,” said SGMT CEO and director Tony Raynor (https://ibn.fm/MTzQp). “And it’s all thanks to our recently completed construction in the Waste Management (‘WM’) facility in central Florida.”
The July 2020 construction at the facility in Apopka, Florida, included a dual line mulch bagger and fully automated electric grinding screen operation. With the new fully electric equipment coming online, the company can increase its mulch production by four million bags per year within one shift. In addition, the new operations will allow full vertical integration at WM’s landfill by utilizing unused debris that is typically buried. Now the unused debris can be reused and branded into a premium mulch product onsite.
“This is a pivotal advancement,” said Raynor commented. “With our strong relationship with Waste Management, we are progressing toward achieving true green sustainability.
Mulch Manufacturing is part of the Sustainable Green Team LTD, which was created by combining the resources of three companies that were leaders In their specialties: Mulch Manufacturing, National Storm Recovery and Central Florida Arbor Care. As a result, SGMT has the expertise to address the needs of each of the combined customers with a new level of quality and cost effectiveness.
The Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling, and removal and bio-mass recycling, as well as manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.
To learn more about the Sustainable Green Team, view the company’s investor presentation at https://ibn.fm/vLpB2. For more information about Mulch Manufacturing, visit www.MulchMfg.com.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
A new study conducted by researchers at the Queen Mary University of London has produced innovative biomarkers that can be used to predict patient responsiveness to DMARDs (disease-modifying anti-rheumatic drugs). Rheumatoid arthritis is an inflammatory disorder that can affect not only one’s joints but also blood vessels, heart, lungs, eyes and skin. The disease causes painful swelling that results in joint deformity and bone erosion.
Patients with rheumatoid arthritis are usually treated using disease-modifying anti-rheumatic drugs. This is despite the fact that almost 50% of rheumatoid arthritis patients are unresponsive to DMARD treatment. Up until now, no method was available to determine if an individual would respond to the treatment effectively.
This new study, published in “Nature Communications,” a science journal, showed that predictions about a patient’s ability to respond to these anti-rheumatic drugs could be made by measuring the levels of specific tiny molecules produced by essential fatty acids in an individuals’ blood. These essential fatty acids usually regulate inflammation and are called specialized pro-resolving mediators.
Professor Jesmond Dalli, the study’s lead author, is from Queen Mary University of London. He has stated that a majority of patients who suffered from rheumatoid arthritis were unresponsive to these anti-rheumatic drugs and were therefore exposed to the drugs’ side effects unnecessarily. Additionally, it takes an average of about six months from initiation of treatment to find out if a patient will or will not respond to these drugs. The disease worsens for patients who do not respond to these drugs before they are able to get a treatment that may work for them.
Dalli explained that the study was carried out using blood samples from healthy rheumatoid arthritis patients who were either unresponsive or responsive to treatment. The samples were collected six months after DMARD treatment began or before initiation of treatment was started. The researchers then used mass spectrometry-based techniques simultaneously with artificial intelligence methods to measure protective molecule levels and also identify molecules that can forecast responses to treatment.
The study recommends that the blood levels of the mediator group, which have been determined in the paper, should be measured. Measuring those blood levers will help forecast the responsiveness of rheumatoid arthritis patients to the disease-modifying anti-rheumatic drug treatment. The team of researchers plans to carry out a larger study to assess their initial findings and find out whether those findings can be applied to a larger patient group.
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is one biomedical company you should watch. The company focuses on developing organ-targeted therapies, especially those for primary and metastatic cancers affecting the central nervous system and the brain.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with high unmet medical need conditions, today announced that it will host a conference call and live webcast at 5:30 p.m. Eastern Time on Nov. 12, 2020. Topics will include review of the company’s third quarter 2020 results and an update on its clinical pipeline, including discussion of PCSA’s three clinical-stage drugs (each of which addresses potential billion-dollar markets). Interested parties may join the call by dialing 877-876-9176 (Toll Free) or 785-424-1670 (International) and access the live webcast via the following link: https://ibn.fm/vMLlY.
The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions — medical conditions where patients need treatment options that will improve survival and/or quality of life. The company has assembled a proven regulatory science development team, management team and board of directors. The Processa development team has been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at http://ibn.fm/PCSA
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
The functional mushroom space has no clear leader, allowing for Rritual to target the role as the only premium brand currently on the market
The company’s premium suite of products will be available first online through their website and the Amazon shop
Rritual was the runner up for the Buyer’s Choice Award in the virtual ECRM presentation that connects companies with retail establishments creating business relationships
The company was chosen for a special ECRM program on October 22, 2020, due to its award-winning status, connecting it to major retailers such as ALDI, Costco, Albertsons/Safeway, and Amazon
The current functional food market is valued at more than $275 billion
Rritual Mushrooms is a private company that manufactures premium plant-based products including small-batch elixir powders and premium shots made from medicinal mushrooms and adaptogenic herbs.
Rritual’s mission is to help each and every person meet the demands of modern life with style and ease through mushroom adaptogen products, slated to be sold online and through brick and mortar establishments. Through its management team, the company has developed connections with leading retailers and other establishments to begin rolling out its product offering. The first products will be available online through the Rritual website and an exclusive Amazon shop.
Recently, Rritual took part in a virtual program organized by ECRM, an international organization that connects suppliers and buyers. The virtual program, called “The Whole Body and Mind Wellness,” was the first time any ECRM program curated meetings related specifically to wellness lifestyle. Its goal was to connect major retailers with brands that support the growing consumer interest in health and fitness (https://nnw.fm/ScOza).
Rritual was selected as the runner up for the Buyers Choice Award for its Reishi Relax Elixir, picked by retail buyers from dozens of entries. “Retail buyers selected Rritual for the award because our packaging, design and formulation stood out amongst the dozens of products they evaluated,” CEO David Kerbel said. “Their stamp of approval on our product reinforces what we know: that Rritual products will capture the attention of shoppers on shelves and in e-comm, supporting our anticipated year-one growth.”
Due to this award, Rritual was invited to participate in a special ECRM program that took place on October 22, 2020. This event included major retailers such as ALDI, Costco, Albertsons/Safeway, and Amazon.
Rich in polysaccharides, triterpenes, fatty acids, and amino acids, infused with Ashwagandha root to improve sleep quality and promote stress support, Reishi Relax is just one of the products included in Rritual’s premium suite. The other two leading products are Lion’s Mane Focus, paired with Rhodiola root to support cognitive function and overall brain health, and Chaga Immune, full of bioactive polysaccharides and infused with Eleuthero root to create an optimal environment for the body’s immune system.
The company is still in its early development stages, but it has the potential to become the leading force in the functional mushroom and foods market, amid a vacuum of premium brands in the space. The current functional food market is valued at more than $275 billion, with a global shift supporting wellness and the 7.9% CAGR forecast through 2025.
The demand for functional mushrooms is also forecasted to rise from $23 billion to an increase of $34 billion by 2024. Worldwide, the market is expected to reach $50 billion by 2025 due to the popularity of the superfood’s unique properties and the proven abilities to increase cognitive function, boost immunity, and help manage stress.
NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, announced receipt of new and repeat domestic orders for BolaWrap(R) products and accessories. According to the update, the company has received numerous recent orders from domestic law enforcement agencies and expects to complete shipping next month. In addition, the company today announced the appointment of Jags Gill as its new director of international sales. Based out of London, Gill brings over 15 years of experience in senior sales management across global law enforcement and security sectors. In his new role, Gill will be responsible for managing and driving international sales for WRTC’s products and working closely with president and interim CEO, Tom Smith, to expand the company’s international footprint. “This is our first salesperson living abroad,” Smith said of the appointment. “We are thrilled to have Jags Gill on the team working directly with our international distributors as well as his own direct channels in law enforcement. Jags’ sales and marketing expertise will be a great asset — invaluable as we grow our international business and reputation.”
Wrap Technologies is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury by agencies in cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, LaGrange, St. Cloud and Oak Ridge. For information about the company, please visit www.WrapTechnologies.com.
NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Study results have exciting therapeutic potential across wide range of CNS indications.
VTGN focused on developing new generation of medications to treat anxiety, depression and more.
Company committed to finding treatment to help estimated 264 million people around the world who suffer from depression.
Noting that 17.3 million adults in the United States have had at least one major depressive episode and some 264 million people around the world suffer from depression, VistaGen Therapeutics (NASDAQ: VTGN) is committed to finding effective treatments for depression that reach beyond the current standard of care, which includes oral antidepressants and oral atypical antipsychotics. The company has released data from a second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. The results, which complement findings from a prior preclinical study, indicate that AV-101, when combined with probenecid, substantially increased the brain concentration of its active metabolite, 7-Cl-KYNA, a potent and selective full antagonist of the N-methyl-D-aspartate receptor (NMDAr) glycine co-agonist site. The combination of drugs may therefore reduce rather than block NMDAr signaling—an effect which could carry significant therapeutic potential.
“These new positive results amplify our message that AV-101, when administered in combination with probenecid, has exciting therapeutic potential across a wide range of CNS (central nervous system) indications,” said VistaGen CEO Shawn Singh. “The studies completed to date are promising and will help us determine the best next step in our overall development plan for the combination.”
VistaGen is assessing the potential of the AV-101/probenecid combination as a treatment for multiple CNS disorders, including dyskinesia (unwanted movement) associated with levodopa therapy for Parkinson’s disease, epilepsy, major depressive disorder, neuropathic pain and suicidal ideation (thoughts and behaviors).The company’s efforts currently are focused on developing three new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates, AV-101, PH10 and PH94B, has a differentiated mechanism of action, an exceptional safety profile in all studies to date and therapeutic potential in multiple CNS markets.
For more information, visit the company’s website at www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Monday, November 2nd, 2020UncategorizedComments Off on $VTGN Preclinical Study Data Show Drug Combo’s Innovative Potential in Fight Against Major Depressive Disorder
The UK is one of numerous countries that have pledged to phase out internal combustion-powered vehicles in favor of electric vehicles (“EVs”). In summer 2019, then Prime Minister Theresa May signed into law the groundbreaking target of achieving net-zero carbon emissions by 2050. However, one factor that has consistently stood in the way of widespread EV adoption, especially in the less-affluent boroughs of London, is poor charging infrastructure.
To help combat this, global ride-hailing giant Uber Technologies (NYSE: UBER) has pledged to invest more than £5m in public, electric-vehicle charging infrastructure. Uber’s analysis shows that the concentration of public EV chargers is far higher in more affluent boroughs such as Kensington and Westminster compared to boroughs where its drivers typically drive.
The firm also found that compared to residents of southwest London, drivers in boroughs such as Tower Hamlets and Newham were less likely to live in houses with driveways that allow them to charge EVs overnight. Although Uber concedes that the investment is only a fraction of what is needed, it will announce the investment as part of its efforts to highlight the imbalance across the capital in the installation of charging stations.
The £5m in funding will be invested by 2023 in areas that lack the charging infrastructure neededto support electric vehicles, says Uber’s regional general manager Jamie Heywood. Uber is looking to work with the borough councils in Brent, Newham and Tower Hamlets to decide how the funding will be divided up and spent. “Drivers consistently tell us that having reliable, accessible charging near where they live is a key factor when deciding if they should switch to electric,” Heywood says. “If we address this challenge for professional drivers now, it will help create a mass market for electric vehicles in the years to come. As we all know, this is critical if the U is to achieve our goal to be net-zero.”
At the moment, only about 1,000 of the 45,000 vehicles Uber operates in London are electric, a long way from its goal of electrifying its entire London fleet. Still, the firm is making steady progress in achieving that goal.
By charging its customers a clean-air fee at 15% extra per mile, Uber was able to raise more than £100m to help its drivers transition to electric cars. Earlier this year, Uber also struck a deal with Nissan to supply 2,000 discounted Leafs to London drivers.
Net Element (NASDAQ: NETE) is an interesting firm in the EV space that you should watch. The company is in the final stages of completing a merger with Mullen Technologies Inc., a California-based EV company that has been developing, designing and manufacturing lightweight, high-end cars for decades. It will be intriguing to follow how the new entity formed from a financial services company and an automaker pans out.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Houston-based CNS Pharmaceuticals is preparing to launch Phase 2 clinical testing of a novel brain cancer-fighting drug candidate called Berubicin early next year
The biopharmaceutical company recently announced that a U.S.-based company contracted to make Berubicin has completed its production process and an Italian company working on a dual track in Europe is expected to finish by the end of the year
Berubicin has shown promise in combatting Glioblastoma multiforme, an aggressive form of brain cancer commonly regarded as incurable. One participant in Berubicin’s Phase 1 trial remains cancer-free 14 years after the trial
CNS Pharmaceuticals, with its sublicensee partner WPD Pharmaceuticals, is also preparing for 2 clinical trials in Poland including the first Phase 1 pediatric trial of Berubicin and a parallel Phase 2 trial in adults
The U.S. manufacturer for a novel anthracycline being tested by biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) as a potential new strategy in combatting an inexorable and ultimately fatal type of brain tumor has completed the manufacturing process for the drug candidate, known as Berubicin.
CNS Pharmaceutical engaged Pharmaceutics International, Inc. (“Pii”) to make Berubicin in the United States while BSP Pharmaceuticals S.p.A. (“BSP“) worked on a dual track to make Berubicin in Italy under the company’s strategy of supplying its upcoming Phase 2 trials with sufficient quantities of the orphan drug status product amid the risk of delays in production and shipping as a result of the ongoing COVID-19 pandemic.
Completion of both Pii’s and BSP’s manufacturing of Berubicin moves CNS Pharmaceuticals closer to completing its preparations for filing an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) to fight glioblastoma.
Glioblastoma multiforme (“GBM”) is an aggressive brain cancer that has no known cure, however the Phase 1 trial of Berubicin in 2006 produced some promising results. Of 25 trial participants who were evaluated, 44 percent achieved what the company refers to as “statistically significant improvement in clinical benefit” (https://ibn.fm/tOnAN) while one patient has remained completely cancer-free as of the last evaluation on Feb. 20 — some 14 years after the initial trial phase.
Glioblastoma patients have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis, although the drug temozolomide has been shown effective in temporarily extending the lifespan of fewer than 40 percent of the GBM patients with a specific genetic variation. The persistent cancer tends to recur after surgery and to develop a resistance to temozolomide over time, making an effective therapy in treating it an attractive goal.
The orphan drug designation grants Berubicin certain benefits during its development and provides CNS with the potential for market exclusivity if the drug is approved for combatting malignant gliomas.
“We are extremely pleased to achieve yet another milestone in our preparation efforts and demonstrate our continued ability to execute upon both our operational and clinical strategies in a timely and proficient manner,” CEO John Climaco stated in the news release. “We remain committed to further progressing our trial preparations, as we look forward to initiating a U.S. Phase 2 trial for Berubicin during the first quarter of 2021.”
As further evidence of the company’s progress toward advancing its clinical testing, CNS has contracted with Worldwide Clinical Trials as the research organization, Image Analysis Group as the imaging partner and with Berry Consultants as a biostatistical adviser for its Phase 2 trial design. CNS has also added renowned neuro-oncologist Dr. Patrick Wen to its Scientific Advisory Board.
For more information, visit the company’s website at www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, earlier this year announced the closing of a private placement financing (the “offering”). According to the update, AzurRx secured approximately $6.9 million in gross proceeds from certain accredited investors, with Alexander Capital LP acting as sole placement agent in the offering. The company intends to use net proceeds to eliminate short- and long-term indebtedness, as well as for general working capital purposes including product development. “We are very grateful for the continued support of our investors,” James Sapirstein, president and CEO of AzurRx said in the press release. “This financing allows us to achieve our short-term goals and continue the development of our MS1819 program for the treatment of exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients.”
AzurRx BioPharma is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819-SD recombinant lipase for exocrine pancreatic insufficiency (“EPI”) is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, New York, with scientific operations based in Langlade, France. Additional information on the company can be found at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
A group of researchers associated with various institutions in China has discovered a gut microbe deficiency in children who develop ASD (autism spectrum disorder). This is a developmental disability characterized by stereotyped and repetitive behavior and impaired social communication. In the research, which was published in the “Science Advances” journal, the team of researchers describes their study of gut microbes in autism spectrum disorder children and discusses their findings.
Previous research had suggested that issues with the gut microbiome may be the cause of the development of ASD in the affected children. However, what those issues might be still remains a mystery. In an effort to discover these issues, this research team took a step forward in helping to solve that mystery through their research.
The research involved the collection of stool samples from 40 children who were not on the autism spectrum and an additional 39 subjects who had been diagnosed with ASD. The researchers also took into account the children’s age, the location they lived in and other additional factors.
The reason for identifying gut biome differences is because differences are common between individuals. Each of the stool samples collected underwent metagenomic sequencing. This is the genomic analysis of DNA of microbiota from environmental communities. The purpose of this was to identify whether there is a distinguishable difference between the children who did not have ASD and those who did.
The team of researchers focused primarily on 18 microbiota species that had been linked to autism spectrum disorder in previous research. Doing this helped the team discover differences in the detoxifying enzyme ratios in children with ASD when compared to those of children who do not have ASD. The researchers then tested an additional 65 children who’d been diagnosed with ASD and found the same results.
These findings led the researchers to suggest that autism spectrum disorder may develop in children because the detoxification process in the gut was affected by a compromised gut microbiome. This allowed environmental toxins to enter the bloodstream, where they damaged mitochondria in brain cells, which ultimately led to the development of symptoms related to ASD.
The researchers say that despite the extensive research already done, more work is needed. They suggest that developing a therapy that helps in the detoxification process is possible. This, they say, might help prevent the onset of autism spectrum disorder. The developed therapy may potentially be used to overpower elements that cause the detoxification issues.
Lots of companies are putting the discoveries made about different health conditions to good use. One biomed company you need to watch is AzurRx BioPharma Inc. (NASDAQ: AZRX). AzurRx focuses on using recombinant proteins to develop treatments to address gastrointestinal diseases.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Cybin Corp., a Canada-based, life-science company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://nnw.fm/wPyaa). Drysdale, named an Ernst and Young Entrepreneur of the Year in 2012, brings more than three decades of experience in the health-care sector and will continue to grow the company’s IP portfolio. “With his myriad of business accomplishments, Doug is the ideal leader for Cybin,” stated Cybin co-founder and COO Paul Glavine of the appointment. “We believe that his extensive health-care sector background and international company management skills will help Cybin strengthen partnerships, develop strategic alliances and expand our international presence. We believe his strong leadership experience will help focus Cybin during our initial path to profitability.”
Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Knightscope recently named Ms. Mallorie Burak as Executive Vice President and Chief Financial Officer
The company’s autonomous security robots use proprietary technology, combining robotics, self-driving capabilities, and artificial intelligence
Game changing technology has now been in operation over 1 million hours and is operating across 5 time zones 24/7/365
Knightscope is a leader in the development of autonomous security capabilities. The company designs and builds Autonomous Security Robots (“ASRs”), which use Knightscope’s proprietary technology combining robotics, self-driving technologies, and artificial intelligence.
The ASRs have proven to enhance the safety at hospitals, manufacturing plants, logistics facilities, schools, businesses, parking lots, and corporate campuses. This level of versatility enables Knightscope to disrupt the $500 billion security industry by offering reliable and cost-effective security solutions for a wide range of scenarios and locations – even during a pandemic. Knightscope currently has three models on the market, with one currently in long-term development – which all drive over 90 terabytes a year of data per machine to an intuitive browser-based user interface.
K1 ASR – The K1 ASR is the 2018 Security Today New Product of the Year award winner. The K1 is a stationary indoor/outdoor unit that can be put in high-risk areas, lobby and reception areas, and parking lots. The K1 runs 24/7 and can be used at help and assistance points using the two-way intercom feature.
K3 ASR – The K3 is an autonomously recharging indoor patrol ASR. The K3 is fully integrated with the Knightscope Security Operations Center (“KSOC”). Which makes it the smart eyes and ears of malls, warehouses, hospitals, offices, and several other locations where indoor patrol is optimal.
K5 ASR – Primarily used outdoors, the K5 features the KSOC technology and autonomously recharges itself as well. It has been in operation for over 1 million hours and worked through its third winter, and still going strong.
K7 ASR – The K7 is the latest ASR under development. This ASR is planned to handle rougher terrain, making it great for airports, utilities, federal government facilities, and many others. The ASR is also planned to be fully integrated with the KSOC user interface technology.
KSOC – the Knightscope Security Operations Center (“KSOC”) is the browser-based user interface our clients utilize to have the magic of our technology at their fingertips.
Providing real-time access to data around the clock, KSOC also features 360-degree eye-level HD video streaming, people detection, facial recognition, automatic license plate recognition, thermal anomaly detection, and automatic signal detection. The technology is also available to schedule patrols, maintain autonomous charging, analytics, live audio broadcast, two-way intercom, pre-recorded broadcast messages, and the capability to conduct investigations as well as obtain court admissible evidence.
Since Knightscope’s inception, it has raised over $70 million with over 16,000 investors. In preparation for a potential public listing, the company is in the process of raising an additional $25 million. It has already reserved the NASDAQ ticker symbol “KSCP.”
The company recently appointed Ms. Mallorie Burak as Executive Vice President and Chief Financial Officer. Ms. Burak is an experienced financial executive with over 25 years of expertise in many industries that range from early-stage start-ups to multi-national corporations. Ms. Burak’s previous experience includes CFO for ThinFilms Electronics ASA and many other industry leaders in which she held the CFO title. She has a proven track record of creating a high-performing culture with a focus on operational excellence (https://nnw.fm/hYuei).
Knightscope’s core mission is to make the United States of America the safest nation in the world. Through its innovative, proprietary technology, the company plans on supporting the millions of law enforcement and security professionals across the country.
NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://nnw.fm/Knight
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Monday, November 2nd, 2020UncategorizedComments Off on Knightscope, Inc. Creating Change in the Security Industry Through Proprietary Technology to Assist Law Enforcement and Private Security
Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, on Thursday announced results for its third quarter ended September 30, 2020. Among the Q3 highlights, the company reported a 275% growth in net sells, a gross margin of 32% and cash, cash equivalents and short-term investments of $45.1 million. In addition, the company’s board of directors named Tom Smith as its interim CEO, effective October 27, 2020. Marc Thomas stepped down from the CEO role and has been appointed to the newly created position of chief government affairs officer. “We are very excited for Tom to assume the additional responsibilities of Interim CEO as we continue to execute on our mission,” said Scot Cohen, executive chairman of the board. “Our goal is to have remote restraint become standard for every police officer worldwide. With 27 years of industry experience, Tom energizes the entire organization and knows the industry extremely well. Marc’s background, skills and passion will help drive change within government entities in this new role during these unprecedented times. As a White House Fellow with an exemplary military background and legislative experience, Marc’s ability to work with government leaders will enhance our position with police and security forces adoption of our technology and training which de-escalates conflict.”
Wrap Technologies is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury by agencies in cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, LaGrange, St. Cloud and Oak Ridge. For information about the company, please visit www.WrapTechnologies.com.
NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent BioWorld article titled, “CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate.” The publication discusses the merging of Affamed Therapeutics Ltd., an emerging biopharmaceutical company focused on opthamology markets in Greater China and funded by the large global venture capital firm, CBC Group, and EverInsight Therapeutics Inc., a biopharmaceutical company focused on central nervous system disorders and also funded by CBC Group. EverInsight and VistaGen entered into an exclusive development and commercialization agreement for VistaGen’s PH94B neuroactive nasal spray, a Phase 3-entering drug candidate for treatment of social anxiety disorder, earlier this year (https://ibn.fm/W6BOk). Under that agreement, VistaGen received a non-dilutive upfront payment of $5 million and, if Phase 3 development is successful, is eligible for up to $172 million in development and commercial milestone payment, plus royalties on commercial sales. According to the article, Affamed aims to bring in late-stage assets for China and other Asian markets focused on central nervous system and ophthalmology. As a result of the merger, VistaGen will work closely with the combined Affamed/EverInsight team on Phase 3 development and commercialization of PH94B in Greater China, South Korea and Southeast Asia. As noted in the article regarding the Affamed/EverInsight merger: “’In addition to bringing together complementary businesses, the combination strengthens the combined company’s global R&D capabilities,’ Affamed’s CEO Dayao Zhao told BioWorld. After the merger, Affamed now has a neurosteroid nasal spray, PH94B, which is moving into phase III development for social anxiety disorder with licensing rights from Vistagen Therapeutics Inc. in greater China, Korea and Southeast Asia.”
VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
A global study that investigated the predisposition of individuals to cannabis use disorder has determined a link between a region of DNA near the FOXP2 gene and cannabis use disorder (“CUD”), previously associated with risk-taking behavior.
A press release notes that researchers from the Washington University School of Medicine studied DNA and other data from about 360,000 individuals who did not have a CUD diagnosis and 21,000 individuals who were diagnosed with CUD.
The research team determined two regions in human DNA — the CHRNA2 gene, which has previously been associated with nicotine addiction and CUD, and the FOXP2 gene. Researchers discovered that both these genes contributed to the risk of becoming dependent on marijuana.
Arpana Agrawal, a professor of psychiatry and the senior study investigator, noted that in roughly 50% of individuals who used marijuana, genetics played a role in those who developed problems with marijuana use. He pointed out that genetic pathways could be used to develop better treatments for marijuana addiction in the future.
The research findings, which were published in “Lancet Psychiatry,” show that some individuals may be vulnerable to CUD before they even smoke their first joints. The reason for this, the researchers note, is because children who had higher genetic susceptibility for severe problems with marijuana were found to have, on average, a marginally lower volume of white matter in their brains. Researchers mentioned behavioral factors such as educational attainment, schizophrenia and risk-taking to be of interest.
In the statement, the first author, Emma Johnson, states that while susceptibility to using marijuana is correlated with higher educational attainment, genetic liability for problematic cannabis use is associated with less education. She adds that it’s also possible that those who use marijuana on occasion but develop no addiction may be genetically predisposed to other protective influences, such as more years of education.
Agrawal observed that many individuals may consider marijuana to be less addictive in comparison to other drugs. However, research findings clearly show that individuals can become dependent on marijuana and that CUD has biological and genetic foundations.
The research study notes that the possibility of genetic liability to cannabis use disorder in individuals who were unexposed has major implications for the public health sector. Another study published in “Lancet Psychiatry” noted that CBD could be used as a new treatment to help treat cannabis use disorder. However, it is unclear what doses might be safe or effective.
The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) is a company in the cannabis sector that you should watch. The company not only makes the best-tasting alkaline water, but they also make broad and full-spectrum hemp-infused products.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, announced completion of its two-year 2018 and 2019 audit to commence the form-10 process to become fully reporting and for future uplisting. In addition, SGTM announced that its wholly owned subsidiary Mulch Manufacturing Inc. will be supplying quality mulch products and services to 7-Eleven stores throughout the Midwest U.S. and western New York, slated to commence in 2021. According to the update, the contract was received a week after the company closed an annual mulch supply contract with the City of Vero Beach, Florida. “Thanks to our VP of Sales Paul Stolly, we continue to secure major international chain accounts to start 2021 strong, commencing with 7-Eleven Inc.’s Midwest U.S. and western New York locations,” SGTM’s CEO and Director Tony Raynor said in the news release. “This allows us to build brand integrity and supply for future expansion as we progress.”
Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential, and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit http://ibn.fm/NYk36
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Friday, October 30th, 2020UncategorizedComments Off on $SGTM Announces Audit Completion, Preparation for Uplisting, Receipt of New Order from 7-Eleven Stores
SGTM secures new soil and mulch contracts through subsidiary Mulch Manufacturing Inc. to supply The Kroger Co. and Circle K
Subsidiary Central Florida Arborcare awarded contract with Lake County, Florida
Mulch Manufacturing Inc. received contract renewal from Menards Inc.
Q2 results include $12.3 million revenue, $3.4 million gross profit
Sustainable Green Team (OTC: SGTM) takes environmental stewardship seriously by providing environmentally beneficial solutions for storm waste disposal that transform landfill-bound trees into next-generation organic mulch products and certified playground surface material. Despite the global recession, the company continues to grow. Through its subsidiary Mulch Manufacturing Inc., SGTM has been awarded contracts to supply The Kroger Co. and Alimentation Couche-Tard Inc. – specifically, for three divisions of its Circle K subsidiary.
The Kroger Co. is the largest supermarket in the United States and the fifth-largest in the world, with roughly 2,750 supermarkets and multi-department stores. The mulch and soil purchasing agreement with Mulch Manufacturing will have SGTM supply Kroger’s Louisville, Kentucky division of 94 stores with a variety of mulch products that include varieties of pine, cypress and cedar.
“Securing a mulch and soil purchasing agreement with the Louisville, Kentucky division of The Kroger Company is an honor and the first step to expand further into their other divisions,” said SGTM CEO and Director Tony Raynor (https://ibn.fm/QEy1u).
Along with The Kroger Co., Mulch Manufacturing was awarded another contract with Alimentation Couche-Tard Inc. to supply three divisions of its Circle K subsidiary – its largest and most international brand. Comprising roughly 9,700 locations in North America, 2,700 in Europe and an additional 2,400 stores worldwide, Circle-K is a recognized brand that spans the Americas all the way to Asia.
“Obtaining three (divisions) for Circle K mulch contracts for 2021 gives us an amazing opportunity to build a relationship with their brand and expand throughout more stores,” said Raynor in recent statements (https://ibn.fm/l3d0v). “We have been blessed to be offered these amazing opportunities from large chain accounts to help further expand our brand and overall exposure.”
Along with these contracts, SGTM has secured agreements through its subsidiary Central Florida Arborcare to provide tree services to Lake County, Florida. This came shortly after being awarded a mulch packaging contract renewal from Menards Inc., the third-largest home improvement chain in the United States with 350 stores across 15 states.
SGTM also provided remediation efforts in the wake of Hurricane Laura through its strategic partner, ArborPro of Mississippi Inc., that diverted damaged trees and other vegetation from landfills. The busy hurricane season contributed significantly to the company’s bottom line this quarter that included an impressive $12.3 million in revenue and $3.4 million in gross profit (https://ibn.fm/mml8i).
SGTM’s expansion strategy combines organic growth, profitable acquisitions and strategic partnerships throughout the United States. The company has a strong commitment to environmental sustainability that served as a primary motivation behind their name and ticker change from National Storm Recovery Inc. (OTC: NSRI) to Sustainable Green Team, Ltd. (OTC: SGTM). Besides driving its environmental mission forward, the company is also dedicated to maximizing shareholder value, particularly for investors that seek profitable opportunities for ethical investing during this challenging economic period.
To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/jzI4b
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Friday, October 30th, 2020UncategorizedComments Off on $SGTM New Contracts with Kroger and Circle-K Ensure Steady Growth, Profits for Sustainable Green Team
SRAX (NASDAQ: SRAX), an innovative fintech solutions provider that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire, today announced that it has sold its remaining interest in the SRAX MD asset. “Our SEQUIRE platform is rapidly growing and we are focused on the continued expansion of this business. We believe that selling the MD ownership stake at this time reinforces our goal of being 100% focused on providing our platform and services to public companies,” said Christopher Miglino, founder and CEO of SRAX. “This capital will be effective in helping us accelerate growth. This asset currently sits on our balance sheet with a zero basis, so this capital will go directly to improving our balance sheet. This transaction combined with moving BIGtoken to its own public company brings clarity to our mission going forward.”
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
A new study conducted by the University of New South Wales has discovered that right now is the most dangerous time for individuals with NCDs (noncommunicable diseases) such as cardiovascular conditions, respiratory problems, cancer and diabetes — primarily because of the COVID-19 pandemic.
The study found that individuals with NCDs were more likely to contract the virus and succumb to it, especially since their exposure to NCD risk factors such as unhealthy diets, social isolation and substance abuse has increased amid the pandemic.
The researchers also discovered that the coronavirus disrupted essential public health services, which many individuals who live with NCDs rely on to manage their conditions. The study, published in “Frontiers in Public Health,” examined the literature on the collaborative effect of COVID-19 on individuals with NCDs in middle-income and low-income countries such as Nigeria, Pakistan, Nepal, Bangladesh, India and Brazil. The study, which was a collaboration between public health researchers in India, Bangladesh, Nepal and UNSW, analyzed roughly 50 studies.
Uday Yadav, the lead author, stated that the interaction between COVID-19 and NCDs was vital to study as international data showed that coronavirus-related deaths were disproportionately high among people with noncommunicable diseases. He added that this finding illustrated the negative effect of the coronavirus syndemic or a synergistic epidemic. This term describes the interrelationship between the various socio-ecological and biological factors behind NCDs and COVID-19.
In order to determine the effect of the future pandemics and the coronavirus on individuals with noncommunicable diseases, the researchers analyzed the data through a syndemic lens. Yadav notes that the coronavirus syndemic will persist, just as noncommunicable diseases affect individuals in the long term.
Yadav also explained that NCDs occurred as a result of a combination of behavioral, environmental, physiological and genetic factors. He noted that it was therefore no surprise that the exposure of patients with noncommunicable diseases to NCD risk factors had grown during the pandemic. This made them more susceptible to contracting the coronavirus due to the syndemic interaction between socio-ecological and biological factors.
He added that the evidence the researchers analyzed indicated poor self-management of NCDs at a community level. The research findings were used to recommend strategies for the health-care sector that would help better manage individuals with NCDs in light of the coronavirus syndemic.
One point Yadav noted was the need to invest in a preventative health-care system, which would not only lead to a decline in the occurrence of noncommunicable diseases but also reduce health-care costs in the long run and strengthen resilience against future pandemics.
One interesting company that you should watch in the biomedical sector is Predictive Oncology (NASDAQ: POAI). The company focuses on drug discovery and the use of analytics as well as artificial intelligence to offer personalized medicine to cancer patients.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the launch of new branding for its upcoming oncology clinical trials. The trials combine Genprex’s lead drug candidate, REQORSA(TM) (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso(R) (osimertinib), which received U.S. Food and Drug Administration (“FDA”) Fast Track Designation earlier this year, as well as the combination of REQORSA with Merck’s Keytruda(R) (pembrolizumab), for the treatment of non-small cell lung cancer (“NSCLC”). “We are enthusiastically preparing for our upcoming clinical trials and are excited to launch the adoption of this branding,” said Rodney Varner, president and chief executive officer of Genprex. “We believe the Acclaim brand communicates our passion for providing hope to NSCLC patients for important new treatment options in the fight against this devastating disease and aligns us with the clinical, medical and patient communities.”
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “GPX-001” (“quaratusugene ozeplasmid”), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s “Tagrisso(R)”) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information about the company, visit www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
The COVID-19 pandemic has made it hard for companies to negotiate deals, as evidenced by the Freeport-McMoRan copper benchmark deal. Instead of personally receiving key customers during the London Metal Exchange Week, miners have resorted to using virtual meetings, whose progress is slower than traditional face-to-face meetings, to hammer out deals.
Apart from impacting gatherings, the pandemic is also affecting mine supply and stirring up market uncertainty. Javier Targhetta, Freeport’s senior VP of sales and marketing, expects that the deficit of copper concentrate in the market will continue. He adds that prior to the pandemic, inflexible supply of concentrates had allowed the company to strike deals that offered the lowest processing fees in almost a decade.
The onset of the pandemic significantly affected copper supply from mines in South America, while imports into China reached peak levels as the economy of the country ricocheted. Targhetta adds that while negotiations of next year are still in the early stages, they projected a deficit for concentrates. This means that the company doesn’t expect any major changes in the refining and treatment charges it gives smelters to turn the ores mined into metal.
Freeport is listed as the world’s largest copper miner, so the deals the company signs with its Asian consumers set the standard for the rest of the industry. Additionally, Freeport negotiations are closely followed by investors as a gauge for demand and supply for the coming year.
In an emailed note, analysts of JPMorgan Chase & Co stated that, after virtual meetings which were held over a week, the JPMorgan team’s bullish view on copper that was first established in April and renewed in August has not changed. It is predicted that prices may reach $7500 a ton in next year’s second quarter.
Targhetta adds that higher prices should provide miners with an incentive to maximize their 2021 output, which may help to reduce some of the strain on supply. He expects changes in the processing fees for 2021 to be minimal. However, smelters are asking for a significant increase to help sustain their margins.
Aurubis is the largest copper producer in Europe. Its executive board chairman, Roland Harring, states that the refining and treatment charges are unreasonably low. He looks forward to when the industry will be able to iron out commercial disagreements in person once more.
Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) is a mining sector player you should watch. This company focuses on producing uranium and vanadium, both of which have been designated by the U.S. federal government as critical minerals.
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
For many living with heart and kidney diseases, taking care of their health includes managing their diets to suit medical recommendations that restrict the consumption of some nutrients. While this might be easy for some, a majority find it hard to follow these recommendations without tracking their nutrition through the day.
To help with this, assistant professor and nephrologist Dr. Ibrahim Elali has created DecideDiet. This free smartphone app allows patients to manually record or scan the bar code of the food they are about to eat. The app automatically evaluates the potassium, or sodium content, of the food item then rates it either red, yellow or green.
The app is designed to especially support individuals living with chronic diseases, to help relieve some of the burden of monitoring these ailments.
Users of the app should strive to eat no less than 75% of foods rated green while avoiding consumption of those rated red. The system helps users not only on an everyday basis but also over a period of time by learning to steer clear of foods with high potassium and sodium.
Elali explains that it usually takes about six months for an individual to adapt to a low-salt diet. To help with tracking food intake, the “basket” on the app documents the food entered into the system throughout the day and over the course of one- to three-month period.
Additionally, the app could possibly be used to carry out a conversation between patients and their health-care providers. Questions concerning their diet can easily be posed and the availability of data on their nutrition and the ability to simply share the information between devices only makes it easier for healthcare providers to provide more accurate information.
Other nutrition apps focus mostly on weight loss and counting calories, which leaves a niche in the market for the app to fill. Elali credits the idea for the app to the interactions he had with his own patients.
Typically doctors give patients a pamphlet about dietary recommendations and count on the patients to read food labels and track their food intake themselves. The app makes this easier, and considering 81% of grown-ups are smartphone users, the app is also accessible for a majority of those living with chronic heart and renal diseases. Its digital approach allows patients to take ownership of their care and makes them feel more involved.
However, DecideDiet has no data about the phosphorous content in foods. This is mainly due to the lack of requirements by the FDA for companies to report phosphorous on nutritional labels, as they are required to do with potassium and sodium.
On the whole though, DecideDiet has the potential to positively influence how patients and doctors approach the care of certain conditions, making it an innovative and useful tool to have.
An interesting company to watch closely is CNS Pharmaceuticals Inc. (NASDAQ: CNSP). This clinical-stage biotech firm focuses on developing treatments for metastatic and primary cancers, especially those afflicting the central nervous system and the brain.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, on Thursday announced that PharmHouse Inc., its 49%-owned joint venture, has received approval from the Ontario Superior Court of Justice to commence its Sale and Investor Solicitation Process (“SISP”). According to the update, the SISP is intended to solicit interest in, and opportunities for, a sale of or investment in all or part of PharmHouse’s assets or business. This may include a restructuring, recapitalization or other form of reorganization. PharmHouse has engaged BMO Capital Markets (“BMO”) to lead the SISP with oversight from Ernst and Young Inc. (“E&Y”), the monitor in PharmHouse’s Companies’ Creditors Arrangement Act (“CCAA”) proceedings.
Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 18 companies across various segments of the cannabis value chain. The company believes that bringing together people, capital and ideas raises the potential of the entire cannabis industry. By leveraging industry insights, in-house expertise and thesis-driven approach to investing, Canopy Rivers aims to provide shareholders exposure to specialized and disruptive cannabis companies. Canopy Rivers’ mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with its portfolio, the company is helping build the cannabis industry of tomorrow, today. For more information, visit www.CanopyRivers.com.
NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://cnw.fm/CNPOF
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
Rritual, a plant-based consumer wellness brand, was selected as runner up for the Buyers Choice Award at last week’s virtual ECRM program. According to an article on Business Wire, Rritual’s Reishi Relax Elixir was selected for the award among dozens of entries evaluated by retail buyers. “Retail buyers selected Rritual for the award because our packaging, design and formulation stood out amongst the dozens of products they evaluated,” said David Kerbel, CEO of Rritual. “Their stamp of approval on our product reinforces what we know: that Rritual products will capture the attention of shoppers on shelves and in e-comm, supporting our anticipated year-one growth.”
Rritual is a plant-based consumer wellness brand dedicated to creating simple, pure, yet effective plant-based health products that are mindfully designed to also facilitate the practice of daily self-care, so that the health of the whole body, mind & spirit is supported. Backed by a leading team of scientists, doctors, nutritionists, and experts across the wellness space, Rritual has entered the market with their flagship collection of certified organic Mushroom and Adaptogen Elixir Mix powders, offering products made with the most-popular mushrooms and in the top need-state health categories: Lion’s Mane Focus, Reishi Relax, and Chaga Immune. For more information, visit the company’s website at www.WeAreRritual.com or visit Twitter, Instagram, LinkedIn and Facebook.
NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER), a producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products, has added health and wellness, CBD-focused, direct-store delivery (DSD) distributor BettermentRS to its list of distributors. The move will enhance WTER’s convenience and grocery store CBD-sales growth. Based on recent research, sales of hemp-derived CBD products in the United States totaled $4.2 billion in 2019, which represents a 562% increase over the previous year. During the same period, sales of CBD products at c-stores and gas stores grew by more than 2,275%, topping out $122 million. The research also noted that CBD-infused drinks, tinctures and topicals are growth opportunities in the channel. In addition, the research reported that CBD drinks were valued at $52 million in c-store sales in 2019 and that CBD drinks are projected to remain popular among new consumers. “We are thrilled to partner with BettermentRS to represent A88CBD brand to some of the nation’s largest and fast-growing retail chains,” said The Alkaline Water Company president and CEO Ricky Wright in the press release. “BettermentRS will provide sales management, marketing, and logistics expertise to accelerate sales for our A88CBD line of products, particularly in the convenience store channel. CBD sales in the c-store channel are booming and represent a tremendous opportunity for our in-demand lifestyle brands. Sales of hemp-derived CBD products in the c-store channel were approximately $122 million in 2019 and grew roughly four times faster than the overall CDB market. BettermentRS will work closely with our sales team to introduce our brands to large accounts, including aforementioned, 7-Eleven and YesWay. . . .As a trusted national brand, we now offer a robust line of high-quality, lab-tested CBD topical and ingestible products. Our recent product announcements include gummies and CBD infused lemon-lime flavored water for our ingestibles line and deep relief cream and bath bombs for our topical line. With additional exciting new products and flavors coming soon and a growing base of strong channel partners, our A88CBD brand is well-positioned to capitalize on the increasing demand for CBD products across various trade channels.”
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
Sustainable Green Team, Ltd. (OTC: SGTM) (“SGTM” or the “Company”), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announces that its 2 year 2018 & 2019 audit has been completed to commence FORM-10 process to become fully reporting and for future uplisting.
The completed audit recorded $2,084,725 in revenue and $103,343 gross profit for the year end 2019, respectively $508,591 and ($9,609) for the year end 2018. As of June 2020’s 6 month uploaded quarter , the Company has recorded $18,637,665 in revenue and $5,081,772 gross profit. An increase of $16,552,940 in revenue and an increase of $4,978,429 gross profit.
Within the first half of 2020, operating 6 month, the Company has recorded 794% increase in revenue and 4,817% increase in gross profit compared to 2019’s 12 months of operations.
SGTM’s CEO and Director Tony Raynor states, “I’m truly blessed and proud of my team not only to complete our first 2 year audit but, to witness our catapult achievement. It’s thanks to my team and partners we have been able to achieve so much and progress with continue growth. Now with out audit complete we are able to take our next major step on taking SGTM fully reporting and work our way to ultimately achieving NASDAQ tier listing.” Mr. Raynor continues with, “We are currently in discussion with multiple SEC legal counsel firms to see whom would fit best with our team and assist us on not only achieving every step along the way to be listed on the NASDAQ but, to assure that we stay complaint with the SEC to provide transparency to our shareholders.”
Mr. Raynor ends with, “We plan on uploading our September 2020 quarter early November and updating our shareholders on our FORM-10 process as we progress.”
About Sustainable Green Team, Ltd. (SGTM)
Sustainable Green Team, Ltd. (“SGTM”), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The Company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The Company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through its tree services division and collection sites and then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The Company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and are positioned for rapid growth from the resulting synergistic opportunities identified. The Company’s customers include governmental, residential and commercial clients.
SGTM currently has two wholly owned subsidiaries to efficiently asses areas, recover, manufacture, and distribute:
National Storm Recovery, LLC
National Storm Recovery, LLC (“NSR”), is composed of a team that has expertise in dangerous tree removal, debris hauling and debris management. The Company’s management team assesses storms by deploying its mobile command center to designated sites and then strategizing with its national partners, which include government agencies, prime contractors and subcontractors.
Central Florida Arborcare(“CFA”), a DBA of NSR has spent more than 40 years perfecting their technique for proper tree care, removal, and services. From tree removal, stump grinding, tree care, grapple hauling, and storm recovery, CFA ensures properties remain safe and businesses can continue as usual.
Mulch Manufacturing, Inc. (“MMI”), being vertically integrated receiving large volume of wood fiber recovered from Central Florida Arborcare to feed raw material needs, MMI has the product line and distribution system to address a substantial customer base which can be expanded.
For additional information regarding SGTM’s operations, expansion plans and production facilities, view the Company’s presentation .
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions, are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. No information in this press release should be construed in any matter whatsoever as an indication of the future performance of the Company’s revenues, financial condition or stock price.
Company Contact:
Anthony Raynor
CEO & Director
407.886.8733 Office
Thursday, October 29th, 2020UncategorizedComments Off on $SGTM Completes 2 Year Audit to Commence FORM-10 Process to become Fully Reporting and for Future Uplisting
